What Revelation Biosciences Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 7 | 24 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 720,255 | 724,168 |
| Disposed | 208,073 | 258,607 |
| Net activity | +512,182 | +465,561 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Zygmont Chester Stanley Iii | Chief Financial Officer | Aug 17 | Gift · G | +208,073 | — | — | 300,136 |
| Zygmont Chester Stanley Iii | Chief Financial Officer | Aug 17 | Gift · G | −208,073 | — | — | 0 |
| Zygmont Chester Stanley Iii | Chief Financial Officer | Aug 17 | Grant / award · A | +208,073 | — | — | 208,073 |
| Chawla Lakhmir S | Director | Aug 17 | Grant / award · A | +32,011 | — | — | 44,169 |
| Roper Jess | Director | Aug 17 | Grant / award · A | +32,011 | — | — | 44,839 |
| Rolke James | Chief Executive Officer | Aug 17 | Grant / award · A | +208,076 | — | — | 422,814 |
| Carver Jennifer | Director | Aug 17 | Grant / award · A | +32,011 | — | — | 44,769 |
| Zygmont Chester Stanley Iii | Chief Financial Officer | Apr 30 | Withheld — tax / exercise cost · F | −13,285 | $1.10 | −$14.6K | 92,063 |
| Rolke James | Chief Executive Officer | Apr 30 | Withheld — tax / exercise cost · F | −10,115 | $1.13 | −$11.4K | 214,738 |
| Zygmont Chester Stanley Iii | Chief Financial Officer | Feb 04 | Withheld — tax / exercise cost · F | −13,100 | $1.65 | −$21.6K | 105,348 |
| Rolke James | Chief Executive Officer | Feb 03 | Withheld — tax / exercise cost · F | −8,521 | $1.86 | −$15.8K | 224,853 |
| Carver Jennifer | Director | Feb 03 | Withheld — tax / exercise cost · F | −1,661 | $1.87 | −$3.11K | 12,758 |
| Chawla Lakhmir S | Director | Feb 03 | Withheld — tax / exercise cost · F | −2,261 | $1.85 | −$4.18K | 12,158 |
| Roper Jess | Director | Feb 03 | Withheld — tax / exercise cost · F | −1,591 | $1.85 | −$2.94K | 12,828 |
| Roper Jess | Director | Jan 08 | Grant / award · A | +41,981 | $0.90 | +$37.8K | 57,667 |
| Carver Jennifer | Director | Jan 08 | Grant / award · A | +41,981 | $0.90 | +$37.8K | 57,669 |
| Zygmont Chester Stanley Iii | Chief Financial Officer | Jan 08 | Grant / award · A | +78,145 | $0.90 | +$70.3K | 473,790 |
| Chawla Lakhmir S | Director | Jan 08 | Grant / award · A | +41,981 | $0.90 | +$37.8K | 57,667 |
| Rolke James | Chief Executive Officer | Jan 08 | Grant / award · A | +532,829 | $0.90 | +$480K | 933,489 |
| Roper Jess | Director | Oct 29 | Grant / award · A | +15,625 | $1.28 | +$20K | 15,686 |
Loading...
